Background. Combined antiretroviral therapy (cART) in human immunodeficiency virus (HIV)-infected pregnant women reduces the maternal-to-child transmission (MTCT) rate from a baseline of 25% to less than 2% when the HIV viral load (VL) is <1,000 copies/mL. The traditional cART is composed of 2 nucleoside reverse transcriptase inhibitor (NRTI-) and 1 protease inhibitor (PI)-class drugs. There is limited information on the effects of VL reduction in pregnancy with alternative cART modalities containing either an integrase strand transfer inhibitor (INSTI) or a non-NRTI (nNRTI).
